FDA grants Roche’s Tecentriq in combination with Abraxane accelerated approval for people with PD-L1-positive, metastatic triple-negative breast cancer

Stacey Gandler
Brand Nourishment

Pat Purcell
Meeting Engagement

Joey Cohen
Medication Adherence

Brenda Snow
Authentic Patient Voice

Frank Burrell
Scientific Storytelling

Daniel Sontupe
Market Access

David Linetsky
Point-of-Care Marketing

Matt Turner
Patient Affordability

Amy Giles
Increasing Engagement

Bud Bilanich
Success Coach

Suma Ramadas, PhD
Medical Affairs

Paul Theisen
Patient Acquisition

Matthew Durham
Omnidynamic Marketing

Liz Kane
Impactful Strategy